Lejus Medical Aktiebolag

Aktiebolaget Hassle

Aktiebolaget Astra

Lejus Medical Aktienbolag

Curt H Appelgren

Eva C Eskilsson

Conny B Bogentoft

Ulf A Odda

Nemo Ivarsson

John A Sjogren

Jonas P Uvdal

Ulf G Smith

Gunnar H Ekenved

The present invention relates to metoprolol succinate, a new therapeutically active compound, and pharmaceutical preparations comprising this new compound.

Metoprolol succinate

The present invention relates to a granular product, whereby it consists of a solid product, which has been provided with a coating of a water-soluble material, which has been provided as a melt, whereby the water-soluble products consists of one or more of polyethylene glycol, xylitol, sorbitol, lactitol, lecitin, and other water-soluble products, as well as a process for preparing the granular product.

Granular product (IV)

Pharmaceutical composition comprising metroprolol succinate

The present invention relates to a multiple-unit-dose comprising L-dopa as pharmaceutically active compound, whereby the composition provides a release of L-dopa in accordance with a test in accordance with U.S. Pharmacopeia Standards in an artificial gastric juice having a pH of at most 1.2 of at most 20% by weight during 1 hr, and in a phosphate buffer according to the same standard a release of at least 35% by weight during 1 hr, and at least 80% by weight during 3 hrs.

Composition comprising L-dopa

The present invention relates to a novel pharmaceutical composition comprising N-acetyl cysteine, wherein the composition releases N-acetyl cysteine in accordance with the United States Pharmacopea Standards (USP XXI, apparatus 2, 50 rpm) in an artificial gastric juice having pH 1.2 to an extent of less than 30% after 1 hr of exposure, and to less than 45% after 2 hrs of exposure, that it releases N-acetyl cysteine in accordance with the same standard in a phosphate buffer having pH 6.8 after 1 hr (3 hrs of total exposure) of at least 30%, and at most 100%, and in the same phosphate buffer of pH 6.8 after 5 hrs (7 hrs of total exposure) of at least 90%. The invention further comprises a method for treating symptoms as well as a method of preparing the composition.

Pharmaceutical dosage with core of N-acetyl cystein

The present invention relates to a granular product comprised of a solid product which has been provided with a coating of a melt of itself, as well as a process for the preparation of the granular product.

Granular product (I)

The present invention relates to a multiple-unit dose composition comprising furosemide as pharmaceutically active compound, whereby the composition gives a release of furosemide in accordance with Dissotest in a buffer having pH 1.5 of at most 4% during hour 1, a release in a buffer having pH 5.5 of at most 7.5% during a consecutive hour (hour 2), a release of furosemide in a buffer having pH 7.5 of at least 65% during a further consecutive hour (hour 3), and a release of furosemide in a buffer having pH 7.5 of at least 90% during a consecutive hour (hour 4).

Diuretic composition

The present invention relates to a process for preparing a rapidly disintegrating core granulate containing a pharmaceutically active compound, which granulate is optionally intended to be coated with a release determining coating, as well as such cores, whereby one adds a pharmaceutically active compound, optionally together with an emulsifier, to a solvent, and optionally treats the composition obtained intensively, optionally while reducing its particle size, distributes the treated composition obtained over a bed of a solid, preferably water soluble material, and dries the agglomerates thus obtained to the so as to form a rapidly disintegrating core granulate.

Process for preparing rapidly disintegrating granulates

Extrusion apparatus

The present invention relates to a process for coating granules, pills, tablets and the like for avoiding excess moistening, and for obtaining an optimal coating time, whereby said products are coated with a coating agent dissolved in a solvent, whereby the products while under movement in the form of a bed of products are sprayed with said solution which is added via a series of spraying nozzles, whereby these are placed side by side over the bed of products to be sprayed, and are placed perpendicular to the direction of movement of the bed, whereby the spray pictures are placed in such a way that overlapping of two adjacent spray pictures on the bed is avoided.

Method for coating granules, pills, and tablets

A device for shaping a semi-moist material into spheres without substantially disintegrating and pulverizing the material, whereby a disc (2) is rotatably arranged in the horizontal plane, which disc (2) on its upper side is arranged to receive a material to be shaped, and thereby is provided with a waffle patterned surface (4), and on its under side is provided with at least two wings (7) arranged substantially radially to the rotational axis of the disc (2), and substantially perpendicular to the under side of the disc (2); that the disc on its upper side, at its periphery has an annular, smooth surface (6), and that the disc (2) is arranged to be rotated against a cylindrical wall (8), whereby between said disc (2) and said wall (8) there is provided an annular slot (9) for allowing the passage of air.

Apparatus for forming material into a ball

According to the present invention an oral pharmaceutical preparation of acetylsalicylic acid is provided which consists of cores containing acetylsalicylic acid as pharmaceutically active component, which cores are coated with a polymer membrane to the formation of coated granules. The preparation is characterized in that the polymer membrane comprises at least one polymer selected from the group consisting of cellulose acetate phtalate and methyl esterified methacrylic acid polymers having a degree of esterification of 45-55%, whereby the amount of such polymer forms 60-45% of the weight of the membrane, and at least one methyl esterified methacrylic acid polymer having a degree of esterification of 65-75% and forming 45-25% of the weight of the membrane, and a plasticizer selected from fatty alcohols and fatty acids forming 4-12% of the weight of the membrane, whereby the membrane represents 5-12 weight % of the composition. With this composition a reduced effect on the gastric mucosa as compared with previously known preparations but retaining good absorbtion properties and a controlled release.

Pharmaceutical preparation

A method of preparing a preparation made up by bodies comprising an active component in decreasing concentration towards the surface of the bodies. The method comprises coating a particle with a composition comprising the active component in a continuous coating operation whereby the concentration of the active component is decreased. The active component may be a drug, a pesticide or an agent having some other effect.

Granule having controlled release properties

Method for preparing preparations having controlled release of an active

A solid pharmaceutical preparation for administration in dosage unit form comprising a therapeutically effective cardiac glycoside, whereby each dosage unit is to comprise a plurality of bodies, each of said bodies having a pharmaceutically indifferent core, a first layer thereon containing the glycoside and a second layer containing a polymer insoluble in gastric juice and soluble in intestinal juice, a process for preparing such preparation and a method of treatment employing the same.

Growing community of inventors

Kungsbacka, Sweden

Curt H Appelgren